Page last updated: 2024-10-29

2-propanol and Fuchs' Endothelial Dystrophy

2-propanol has been researched along with Fuchs' Endothelial Dystrophy in 15 studies

2-Propanol: An isomer of 1-PROPANOL. It is a colorless liquid having disinfectant properties. It is used in the manufacture of acetone and its derivatives and as a solvent. Topically, it is used as an antiseptic.
propan-2-ol : A secondary alcohol that is propane in which one of the hydrogens attached to the central carbon is substituted by a hydroxy group.

Fuchs' Endothelial Dystrophy: Disorder caused by loss of endothelium of the central cornea. It is characterized by hyaline endothelial outgrowths on Descemet's membrane, epithelial blisters, reduced vision, and pain.

Research Excerpts

Excerpt	Relevance	Reference
"Fuchs' endothelial dystrophy was found in 19 patients."	1.33	A novel PITX2 mutation and a polymorphism in a 5-generation family with Axenfeld-Rieger anomaly and coexisting Fuchs' endothelial dystrophy. ( Baumer, A; Gloor, BP; Kniestedt, C; Stuermer, J; Taralczak, M; Thiel, MA, 2006)
"Keratoconus was the most common indication for a penetrating keratoplasty (22."	1.28	Penetrating keratoplasty 1981-1988: clinical indications and pathologic findings. ( Coulter, VL; Craig, MT; Lundergan, MK; Mamalis, N; Olson, RJ, 1991)

Research

Studies (15)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (6.67)	18.7374
1990's	2 (13.33)	18.2507
2000's	3 (20.00)	29.6817
2010's	7 (46.67)	24.3611
2020's	2 (13.33)	2.80

Authors

Authors	Studies
Hayashi, T	2
Hos, D	1
Schrittenlocher, S	1
Siebelmann, S	1
Matthaei, M	1
Franklin, J	1
Clahsen, T	1
Bock, F	1
Bachmann, B	1
Cursiefen, C	2
Onouchi, H	1
Shimizu, T	1
Matsuzawa, A	1
Suzuki, Y	1
Kato, N	1
Tappeiner, C	1
Dreesbach, J	1
Roesel, M	1
Heinz, C	1
Heiligenhaus, A	1
Holtmann, C	1
Spaniol, K	1
Geerling, G	1
Muñoz-Morales, A	1
del Trigo-Zamora, JR	1
Sánchez-Vicente, JL	1
Lozano-Bernal, O	1
Luchena-López, R	1
Russell, HC	1
Srinivasan, S	1
Baryla, J	1
Tokarewicz, AC	1
Rudolph, M	1
Laaser, K	1
Bachmann, BO	1
Epstein, D	1
Kruse, FE	1
Anwar, DS	1
Chu, CY	1
Prasher, P	1
Bowman, RW	1
Mootha, VV	1
Patel, DV	1
Phua, YS	1
McGhee, CN	1
Kniestedt, C	1
Taralczak, M	1
Thiel, MA	1
Stuermer, J	1
Baumer, A	1
Gloor, BP	1
Krey, H	1
Wizemann, A	1
Bourcier, T	1
Laplace, O	1
Touzeau, O	1
Moldovan, SM	1
Borderie, V	1
Laroche, L	1
Loewenstein, A	1
Geyer, O	1
Hourvitz, D	1
Lazar, M	1
Mamalis, N	1
Craig, MT	1
Coulter, VL	1
Lundergan, MK	1
Olson, RJ	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Descemet Endothelial Thickness Comparison Trial[NCT02373137]			Phase 4	38 participants (Actual)	Interventional	2015-01-22	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Best Spectacle-Corrected Visual Acuity

The BSCVA was recorded at 4 meters by a masked refractionist certified for the study using a protocol adapted from the Age-Related Eye Disease Study using Early Treatment Diabetic Retinopathy Study charts: chart R(2110), chart 1(2111), and chart 2(2112) (Precision Vision, Woodstock, IL). (NCT02373137)
Timeframe: 24 Months

Intervention	LogMar (Mean)
UT-DSAEK	0.15
DMEK	0.09

Best Spectacle-Corrected Visual Acuity

Intervention	logMAR (Mean)
UT-DSAEK	0.22
DMEK	0.05

Endothelial Cell Count

(NCT02373137)
Timeframe: 24 months

Intervention	cells/mm^2 (Mean)
UT-DSAEK	1626
DMEK	1400

Adverse Events/Complication Rates

composite measure (NCT02373137)
Timeframe: 3, 6, 12, 24 months

Intervention	new adverse events reported (Number)
	Adverse Events at 3 months	Adverse Events at 6 months	Adverse Events at 12 months	Adverse Events at 24 months
DMEK	6	5	4	0
UT-DSAEK	4	4	1	0

Best Spectacle-Corrected Visual Acuity

Intervention	logMAR (Mean)
	3 Months	12 Months
DMEK	0.11	0.04
UT-DSAEK	0.24	0.16

Corneal Higher-Order Aberrations

As measured by Pentacam (NCT02373137)
Timeframe: 24 months

Intervention	root mean square in micrometers (Mean)
	24 Months Anterior Cornea 4.0-mm	24 Months Posterior Cornea 4.0-mm	24 Months Anterior Cornea 6.0-mm	24 Months Posterior Cornea 6.0-mm
DMEK	0.211	0.086	0.679	0.260
DSAEK	0.215	0.155	0.707	0.450

Corneal Higher-Order Aberrations

Corneal anterior and posterior surface higher-order aberrations (HOA) were measured with Scheimpflug imaging (Pentacam) before surgery and at 3, 6, and 12 months post-operatively. Zernike orders 3-8 were calculated at 4.0- and 6.0-mm-diameter optical zones. The results reported here represent total HOA (Sum of Zernike orders 3-8). Note a single observation was not available for one eye in the DMEK group at 6 months, this was analyzed with last observation carried forward. (NCT02373137)
Timeframe: 3, 6, 12 months

Intervention	root mean square in micrometers (Mean)
	3 Months Anterior Cornea 4.0-mm	3 Months Posterior Cornea 4.0-mm	3 Months Anterior Cornea 6.0-mm	3 Months Posterior Cornea 6.0-mm	6 Months Anterior Cornea 4.0-mm	6 Months Posterior Cornea 4.0-mm	6 Months Anterior Cornea 6.0-mm	6 Months Posterior Cornea 6.0-mm	12 Months Anterior Cornea 4.0-mm	12 Months Posterior Cornea 4.0-mm	12 Months Anterior Cornea 6.0-mm	12 Months Posterior Cornea 6.0-mm
DMEK	0.288	0.116	0.829	0.346	0.243	0.095	0.724	0.288	0.241	0.098	0.723	0.284
UT-DSAEK	0.274	0.217	0.897	0.621	0.230	0.179	0.739	0.505	0.228	0.159	0.725	0.459

Endothelial Cell Count

(NCT02373137)
Timeframe: 3, 6, 12 months

Intervention	cells/mm^2 (Mean)
	3 Months	6 Months	12 Months
DMEK	2037	1963	1855
UT-DSAEK	2114	2113	2070

Graft Failure/Graft Rejection

(NCT02373137)
Timeframe: Baseline 12 months

Intervention	eyes (Count of Units)
	Graft Rejection	Graft Failure
DMEK	0	1
UT-DSAEK	0	1

Graft Thickness

As measured by Optical coherence tomography (OCT) and Pachymetry (NCT02373137)
Timeframe: 3, 6, 12, 24 months

Intervention	root mean square in micrometers (Mean)
	3 months	6 months	12 months	24 months
DMEK	516.5	519.67	521.36	526.88
UT-DSAEK	589.36	592.24	585.96	593.67

Interface Haze

As measured by Pentacam densitometry (NCT02373137)
Timeframe: 24 months

Intervention	eyes (Number)
	Mild Interface Haze at 24 months	Moderate Interface Haze at 24 months	Severe Interface Haze at 24 months
DMEK	0	0	0
UT-DSAEK	0	1	0

Interface Haze

As measured by Pentacam densitometry (NCT02373137)
Timeframe: 3, 6, 12 months

Intervention	eyes (Number)
	Mild Interface Haze at 3 months	Moderate Interface Haze at 3 months	Severe Interface Haze at 3 months	Mild Interface Haze at 6 months	oderate Interface Haze at 6 months	Severe Interface Haze at 6 months	Mild Interface Haze at 12 months	oderate Interface Haze at 12 months	Severe Interface Haze at 12 months
DMEK	1	0	0	1	0	0	0	0	0
UT-DSAEK	2	0	0	2	1	0	0	0	0

National Eye Institute - Visual Functioning Questionnaire (NEI-VFQ)

"The National Eye Institute has developed the validated Visual Functioning Questionnaire (NEI-VFQ) to assess the effect of ocular conditions and vision on patient quality of life. The answers to the questionnaire are transformed into sub-scales, including: general health, general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision. Participants are assigned a numerical value for each sub-scale based on their answers between 0-100, where higher numbers indicate better visual function. These sub-scales are then combined according to National Eye Institute guidelines into an overall composite score for each participant. This overall composite score is also on a scale of 0-100, where higher numbers indicate better visual function.~Composite score based on National Eye Institute guidelines." (NCT02373137)
Timeframe: Baseline, 12 months

Intervention	Composite scores on a scale (Mean)
	Baseline	12 Months
DMEK	72.3	87.3
UT-DSAEK	72.5	85.9

Other Studies

15 other studies available for 2-propanol and Fuchs' Endothelial Dystrophy

Article	Year
Effect of Iris Color on the Outcome of Descemet Membrane Endothelial Keratoplasty. Cornea, 2020, Volume: 39, Issue:7 Topics: Aged; Descemet Stripping Endothelial Keratoplasty; Eye Color; Female; Follow-Up Studies; Fuchs' Endo	2020
Anatomical Changes in the Anterior Chamber Volume After Descemet Membrane Endothelial Keratoplasty. Cornea, 2021, Jun-01, Volume: 40, Issue:6 Topics: Aged; Aged, 80 and over; Anterior Chamber; Blister; Corneal Diseases; Descemet Stripping Endothelial	2021
Clinical manifestation of Fuchs uveitis syndrome in childhood. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2015, Volume: 253, Issue:7 Topics: Adolescent; Adult; Atrophy; Cataract; Child; Child, Preschool; Chronic Disease; Female; Fuchs' Endot	2015
Urrets-Zavalia syndrome after Descemet membrane endothelial keratoplasty. European journal of ophthalmology, 2015, Jul-30, Volume: 25, Issue:5 Topics: Acetazolamide; Aged; Cataract Extraction; Combined Modality Therapy; Descemet Stripping Endothelial	2015
Express implant in Urrets-Zavalia syndrome after descemet's stripping automated endothelial keratoplasty. Archivos de la Sociedad Espanola de Oftalmologia, 2015, Volume: 90, Issue:10 Topics: Air; Descemet Stripping Endothelial Keratoplasty; Drug Resistance; Fuchs' Endothelial Dystrophy; Gla	2015
Urrets-Zavalia syndrome following Descemet's stripping endothelial keratoplasty triple procedure. Clinical & experimental ophthalmology, 2011, Volume: 39, Issue:1 Topics: Aged; Atrophy; Atropine; Cataract; Cyclopentolate; Descemet Stripping Endothelial Keratoplasty; Foll	2011
Pupillary block glaucoma following descemet stripping automated endothelial keratoplasty related to intraoperative floppy-iris syndrome. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2011, Volume: 46, Issue:2 Topics: Adrenergic alpha-1 Receptor Antagonists; Descemet Stripping Endothelial Keratoplasty; Fuchs' Endothe	2011
Corneal higher-order aberrations after Descemet's membrane endothelial keratoplasty. Ophthalmology, 2012, Volume: 119, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Cornea; Corneal Wavefront Aberration; Descemet Stripping Endothelial	2012
Features of Urrets-Zavalia syndrome after descemet stripping automated endothelial keratoplasty. Cornea, 2012, Volume: 31, Issue:11 Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atrophy; Descemet Stripping Endothelial Keratoplas	2012
Clinical and microstructural analysis of patients with hyper-reflective corneal endothelial nuclei imaged by in vivo confocal microscopy. Experimental eye research, 2006, Volume: 82, Issue:4 Topics: Cataract Extraction; Cell Count; Cell Nucleus; Corneal Diseases; Corneal Dystrophies, Hereditary; Co	2006
A novel PITX2 mutation and a polymorphism in a 5-generation family with Axenfeld-Rieger anomaly and coexisting Fuchs' endothelial dystrophy. Ophthalmology, 2006, Volume: 113, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cell Count; Child; Child, Preschoo	2006
[Timolol response in denervational syndromes (author's transl)]. Klinische Monatsblatter fur Augenheilkunde, 1981, Volume: 179, Issue:3 Topics: Fuchs' Endothelial Dystrophy; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Iris; Parasympathe	1981
[Urrets-Zavalia syndrome]. Journal francais d'ophtalmologie, 2001, Volume: 24, Issue:3 Topics: Adult; Atrophy; Female; Follow-Up Studies; Fuchs' Endothelial Dystrophy; Humans; Iris; Iris Diseases	2001
The association of Fuch's corneal endothelial dystrophy with angle closure glaucoma. The British journal of ophthalmology, 1991, Volume: 75, Issue:8 Topics: Aged; Aged, 80 and over; Female; Fuchs' Endothelial Dystrophy; Glaucoma, Angle-Closure; Humans; Iris	1991
Penetrating keratoplasty 1981-1988: clinical indications and pathologic findings. Journal of cataract and refractive surgery, 1991, Volume: 17, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anterior Chamber; Child; Child, Preschool; Corneal Disea	1991